Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTHFree Report) by 7.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,052 shares of the medical equipment provider’s stock after selling 7,084 shares during the quarter. Mutual of America Capital Management LLC owned about 0.14% of Lantheus worth $6,535,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Fairfield Bush & CO. purchased a new stake in Lantheus during the 1st quarter valued at about $177,000. Raymond James & Associates purchased a new position in Lantheus during the 1st quarter valued at about $856,000. Bank of New York Mellon Corp increased its stake in Lantheus by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock worth $34,791,000 after buying an additional 16,422 shares during the period. American Century Companies Inc. boosted its holdings in Lantheus by 14.4% in the first quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock valued at $1,064,000 after purchasing an additional 2,427 shares during the period. Finally, HighTower Advisors LLC purchased a new position in Lantheus in the first quarter worth approximately $354,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LNTH shares. Brookline Capital Management began coverage on shares of Lantheus in a research note on Thursday, November 30th. They set a “buy” rating and a $100.00 price target on the stock. TheStreet downgraded shares of Lantheus from a “b-” rating to a “c” rating in a research report on Monday, December 18th. B. Riley lowered their price objective on shares of Lantheus from $113.00 to $95.00 and set a “buy” rating on the stock in a research note on Wednesday, January 10th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, William Blair downgraded shares of Lantheus from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $108.14.

Get Our Latest Research Report on Lantheus

Insider Activity

In other news, President Paul Blanchfield sold 1,500 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $67.96, for a total value of $101,940.00. Following the completion of the sale, the president now owns 88,651 shares of the company’s stock, valued at $6,024,721.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Lantheus news, President Paul Blanchfield sold 1,500 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $67.96, for a total value of $101,940.00. Following the completion of the transaction, the president now directly owns 88,651 shares of the company’s stock, valued at approximately $6,024,721.96. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Mary Anne Heino sold 11,780 shares of Lantheus stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $63.72, for a total value of $750,621.60. Following the sale, the chief executive officer now directly owns 317,687 shares in the company, valued at $20,243,015.64. The disclosure for this sale can be found here. Insiders have sold 13,962 shares of company stock valued at $893,338 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of Lantheus stock opened at $56.14 on Friday. The stock has a market capitalization of $3.85 billion, a P/E ratio of 39.26 and a beta of 0.53. The company has a current ratio of 5.37, a quick ratio of 5.05 and a debt-to-equity ratio of 0.80. The business’s fifty day moving average price is $60.77 and its 200 day moving average price is $65.79. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $100.85.

About Lantheus

(Free Report)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent.

Read More

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.